Prospective and Longitudinal Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Positive and Negative Pneumonia: Potential Role of Decreased Naïve CD8 in COVID-19 Patients.

Publication date: Dec 30, 2024

Background: During the acute phase of COVID-19, a number of immunological abnormalities have been reported, but few studies longitudinally analyzed the specific subsets of peripheral blood lymphocytes. Methods: In this observational, prospective, and longitudinal study, adult patients developing acute pneumonia during the COVID-19 pandemic have been followed up for 12 months. Peripheral blood lymphocyte subsets were assessed (with a specific focus on the memory markers) at 6 time points after the disease onset until 12 months. Results: A total of 76 patients with acute pneumonia (characterized by a prevalently interstitial pattern of lung inflammation) at the hospital admission (who completed the 12-month follow-up period) were recruited in this study. They were divided into two groups, namely positive (n = 31) and negative (n = 45) patients for the SARS-CoV-2 PCR test. In the acute phase, the general lymphocyte immunophenotyping profile was comparable for most parameters between these groups, except for B cells. When B and T cells were analyzed according to the expression of memory markers, a significant decrease in nacEFve CD8 T cells was observed in the SARS-CoV-2-positive pneumonia group during the acute phase. Notably, this aspect was maintained during the follow-up period for at least 9 months. Conclusions: COVID-19 pneumonia seems to be associated with a lower number of nacEFve CD8 T cells compared to pneumonia patients negative for this virus. This alteration can persist in the convalescent phase.

Open Access PDF

Concepts Keywords
Blood Adult
Immunophenotyping Aged
Pcr CD8-Positive T-Lymphocytes
Pneumonia COVID-19
COVID-19
Female
Humans
Immunologic Memory
Immunophenotyping
Longitudinal Studies
lymphocyte immunophenotype
Lymphocyte Subsets
Male
Middle Aged
pneumonia
Prospective Studies
SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
disease MESH Pneumonia
disease IDO role
disease MESH COVID-19
disease MESH abnormalities
disease IDO blood
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH infections
disease MESH mutation rate
disease IDO host
disease MESH emergency
disease MESH viral infection
disease IDO cell
disease MESH inflammation
disease IDO infection
disease MESH interstitial lung disease
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH chronic renal failure
drug DRUGBANK Immune Globulin Human
disease IDO protein
drug DRUGBANK Edetic Acid
drug DRUGBANK Flunarizine
drug DRUGBANK Aspartame
disease MESH diabetes mellitus
disease MESH chronic renal disease
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Comorbidity
disease MESH Hypertension
disease MESH cardiovascular disease

Original Article

(Visited 5 times, 1 visits today)